{"title":"Optimising follow-up of myocardial infarction in primary care","authors":"M. Kirby","doi":"10.3132/PCCJ.2008.009","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.009","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124183928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A survey of GPs’ views on clinical and cost issues in prescribing statins","authors":"J. M. L. Bejarano","doi":"10.3132/pccj.2008.016","DOIUrl":"https://doi.org/10.3132/pccj.2008.016","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132449895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Age cut-off for aspirin therapy to prevent cardiovascular disease in patients without diabetes","authors":"I. Idris","doi":"10.3132/PCCJ.2009.013","DOIUrl":"https://doi.org/10.3132/PCCJ.2009.013","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124137887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Optimising use of statins in clinical practice: how to achieve the best clinical outcomes for every patient","authors":"C. Diehm","doi":"10.3132/PCCJ.2008.015","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.015","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124357319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Review urges measures to improve PAD management","authors":"G. Stansby, J. Belch","doi":"10.3132/PCCJ.2008.033","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.033","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116083135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
endorse the five major classes of antihypertensives – thiazide diuretics, calcium antagonists, ACE inhibitors, angiotensin receptor antagonists and betablockers – as being suitable for the initiation and maintenance of antihypertensive treatment, alone or in combination. Further, they state that because more than one drug is needed by many patients, there is a futility in emphasising the first class of drugs to be used. Evidence exists for the benefits of each of the drugs we use, although some classes are more appropriate or effective in different ethnic groups or in those with co-morbidities and concurrent prescribing. However, some national societies make it simpler for the primary care team by being more specific. For example, the latest British Hypertension Society (BHS) guidelines specifically recommend drug therapy in all patients with sustained systolic pressures of > 160 mmHg or sustained diastolic pressures > 100 mmHg despite lifestyle measures, and in patients with sustained systolics of 140–159 mmHg or diastolics of 90–99 mmHg where target organ damage is present or where there is evidence of established cardiovascular disease, diabetes or a raised 10-year CHD risk. Beta-blockers have fallen from favour as Introduction F aced with a wide variety of therapies on offer in hypertension management and differences in the available guidelines, although endorsing all therapeutic groups, it can be useful to consider differences that may mean some drugs are more useful than others in certain patients. Age, ethnic group, concurrent pathology, cost and interactions with other therapies will affect our choice. A new study suggests that an angiotensin receptor antagonist, olmesartan, may offer the added benefit of reversing atherosclerotic plaque development. Using a new method for measuring intima media thickness (IMT) – non-invasive 3D ultrasound imaging of the carotid arteries – the Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study showed a significant reduction in plaque size in hypertensive patients with known atherosclerosis who were treated with olmesartan for two years. This is a small, preliminary study, but raises the possibility of reversal of atherosclerosis with a drug that is currently used to reduce raised blood pressure.
{"title":"A new study suggests olmesartan may achieve regression of atherosclerosis","authors":"M. Taboada, G. Jenkins","doi":"10.3132/PCCJ.2008.011","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.011","url":null,"abstract":"endorse the five major classes of antihypertensives – thiazide diuretics, calcium antagonists, ACE inhibitors, angiotensin receptor antagonists and betablockers – as being suitable for the initiation and maintenance of antihypertensive treatment, alone or in combination. Further, they state that because more than one drug is needed by many patients, there is a futility in emphasising the first class of drugs to be used. Evidence exists for the benefits of each of the drugs we use, although some classes are more appropriate or effective in different ethnic groups or in those with co-morbidities and concurrent prescribing. However, some national societies make it simpler for the primary care team by being more specific. For example, the latest British Hypertension Society (BHS) guidelines specifically recommend drug therapy in all patients with sustained systolic pressures of > 160 mmHg or sustained diastolic pressures > 100 mmHg despite lifestyle measures, and in patients with sustained systolics of 140–159 mmHg or diastolics of 90–99 mmHg where target organ damage is present or where there is evidence of established cardiovascular disease, diabetes or a raised 10-year CHD risk. Beta-blockers have fallen from favour as Introduction F aced with a wide variety of therapies on offer in hypertension management and differences in the available guidelines, although endorsing all therapeutic groups, it can be useful to consider differences that may mean some drugs are more useful than others in certain patients. Age, ethnic group, concurrent pathology, cost and interactions with other therapies will affect our choice. A new study suggests that an angiotensin receptor antagonist, olmesartan, may offer the added benefit of reversing atherosclerotic plaque development. Using a new method for measuring intima media thickness (IMT) – non-invasive 3D ultrasound imaging of the carotid arteries – the Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study showed a significant reduction in plaque size in hypertensive patients with known atherosclerosis who were treated with olmesartan for two years. This is a small, preliminary study, but raises the possibility of reversal of atherosclerosis with a drug that is currently used to reduce raised blood pressure.","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126637123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CKD as part of integrated management of vascular risk","authors":"D. O'Donoghue","doi":"10.3132/PCCJ.2009.025","DOIUrl":"https://doi.org/10.3132/PCCJ.2009.025","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123678640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Investigating symptoms suggestive of cardiac arrhythmia in primary care requires a strategy beyond the resting 12-lead electrocardiogram (ECG), as the test is generally only of use while the patient is experiencing discomfort during the recording. This study assessed the use of automated ambulatory ECG monitors in diagnosing cardiac arrhythmias. Design: A retrospective review of patients at one general practice. Participants: 52 consecutive patients (73% female; age 52+18 years, range 22 to 93 years) with symptoms suggestive of cardiac arrhythmia. Method: Automated ECG was recorded for 24 hours. Patients were also given a diary to record symptoms. The ECG reports were examined at the end of the test and correlated with symptoms, patient notes, and history before a decision to refer to secondary care was made. Results: Episodes (> 30 s) of tachycardia (> 120 bpm) were present in 52% of patients and bradycardia (< 50 bpm) in 19%. The most common supraventricular arrhythmia was atrial ectopics, detected in 52% of patients. Three patients (6%) were found to have atrial fibrillation (AF) during the 24-hour test. Ventricular arrhythmia was detected in 71% of patients, with an average ectopic rate of 28+88 per hour (range < 1 to 397 per hour). Overall, 73% of patients were symptomatic during the 24-hour test, with 10% experiencing symptoms on at least 10 occasions. Conclusions: Use of ambulatory ECG in patients with symptoms of cardiac arrhythmia proved feasible and useful in primary care. Results were used as the basis of referrals for 50% of patients tested, and to inform initiation or changes of medication in a further 24% of patients.
{"title":"Ambulatory ECG monitoring in primary care","authors":"G. Kassianos","doi":"10.3132/PCCJ.2008.027","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.027","url":null,"abstract":"Objective: Investigating symptoms suggestive of cardiac arrhythmia in primary care requires a strategy beyond the resting 12-lead electrocardiogram (ECG), as the test is generally only of use while the patient is experiencing discomfort during the recording. This study assessed the use of automated ambulatory ECG monitors in diagnosing cardiac arrhythmias. Design: A retrospective review of patients at one general practice. Participants: 52 consecutive patients (73% female; age 52+18 years, range 22 to 93 years) with symptoms suggestive of cardiac arrhythmia. Method: Automated ECG was recorded for 24 hours. Patients were also given a diary to record symptoms. The ECG reports were examined at the end of the test and correlated with symptoms, patient notes, and history before a decision to refer to secondary care was made. Results: Episodes (> 30 s) of tachycardia (> 120 bpm) were present in 52% of patients and bradycardia (< 50 bpm) in 19%. The most common supraventricular arrhythmia was atrial ectopics, detected in 52% of patients. Three patients (6%) were found to have atrial fibrillation (AF) during the 24-hour test. Ventricular arrhythmia was detected in 71% of patients, with an average ectopic rate of 28+88 per hour (range < 1 to 397 per hour). Overall, 73% of patients were symptomatic during the 24-hour test, with 10% experiencing symptoms on at least 10 occasions. Conclusions: Use of ambulatory ECG in patients with symptoms of cardiac arrhythmia proved feasible and useful in primary care. Results were used as the basis of referrals for 50% of patients tested, and to inform initiation or changes of medication in a further 24% of patients.","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121785945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：